Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026
Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026
Company Deals

Genesis MedTech Acquires Controlling Stake in TUGE Healthcare, Gaining China’s First Domestic 4K+3D+Fluorescence Endoscopic Platform

Fineline Cube Apr 7, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Fineline Cube Apr 8, 2026
Company Drug

Vocabria Receives Positive CHMP Opinion for HIV Treatment in Adolescents

Fineline Cube Dec 17, 2024

GSK plc (NYSE: GSK) has announced that ViiV Healthcare, an HIV specialist majority owned by...

Company Drug

GSK’s Jemperli Receives Positive CHMP Opinion for Endometrial Cancer Indication Extension

Fineline Cube Dec 17, 2024

The UK-based pharmaceutical giant GSK (NYSE: GSK) has received a positive opinion from the European...

Company Drug

GSK’s Jemperli Receives FDA Breakthrough Therapy Designation for Rectal Cancer Treatment

Fineline Cube Dec 17, 2024

UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that it has received Breakthrough Therapy Designation...

Company Drug

CanSino Biologics’ DTcP Vaccine for Infants and Young Children Accepted by NMPA for Review

Fineline Cube Dec 17, 2024

China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) has announced that the National Medical Products...

Company Deals

MicroPort NeuroTech Leads Investment Fund to Advance Brain Science Industry

Fineline Cube Dec 17, 2024

China-based MicroPort NeuroTech Limited (HKG: 2172) has announced its commitment to invest RMB 200 million...

Company Deals

Candid Therapeutics Expands TCE Portfolio with Strategic Partnerships in Autoimmune Disease Treatment

Fineline Cube Dec 17, 2024

US-based Candid Therapeutics Inc. is fulfilling its ambition to become a leader in advancing T-cell...

Company Drug

EMA Grants PRIME Designation to Hansoh Pharmaceutical’s HS-20093 in Collaboration with GSK

Fineline Cube Dec 17, 2024

The European Medicines Agency (EMA) has conferred Priority Medicines (PRIME) designation to HS-20093 (GSK5764227), a...

Company Deals

Bio-Thera Solutions Expands License Deal with SteinCares for Latin American Market

Fineline Cube Dec 17, 2024

China-based Bio-Thera Solutions (SHA: 688177) has announced the addition of a third biosimilar to its...

Company Drug

European CHMP Supports Conditional Approval of MSD’s Welireg for VHL Disease and RCC

Fineline Cube Dec 16, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the European Medicines Agency’s Committee...

Company Drug

EMA’s CHMP Recommends Approval of Bayer’s Acoramidis for ATTR-CM Treatment

Fineline Cube Dec 16, 2024

Bayer’s (ETR: BAYN) acoramidis has received a positive recommendation from the Committee for Medicinal Products...

Policy / Regulatory

Guangdong Province Releases List of Urgent Clinical Drugs and Devices for GBA Cities

Fineline Cube Dec 16, 2024

The medical products administration and health commission of Guangdong province have released a list of...

Company Drug

Sanofi’s Tolebrutinib Earns FDA Breakthrough Designation for Non-Relapsing Secondary Progressive MS

Fineline Cube Dec 16, 2024

Sanofi (NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA) has granted...

Company Medical Device

Roche’s cobas 6800/8800 Systems 2.0 Earn CE Certification, Set for US Market Entry

Fineline Cube Dec 16, 2024

Global healthcare company Roche (SWX: ROG) has announced that its state-of-the-art cobas 6800/8800 Systems 2.0...

Company Drug

ARS Pharmaceuticals’ Neffy Receives Market Filings in Asia-Pacific Region

Fineline Cube Dec 16, 2024

US-based ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has announced that market filings for its intranasal epinephrine...

Company Drug

Fujian Cosunter Pharmaceutical’s GST-HG141 Earns Breakthrough Designation for Chronic Hepatitis B

Fineline Cube Dec 16, 2024

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that it...

Policy / Regulatory

Beijing Conference Outlines 2025 Healthcare Security Goals and 2024 Progress

Fineline Cube Dec 16, 2024

A national conference on healthcare security was recently held in Beijing, reviewing the achievements of...

Company Deals

Quantum Hi-Tech (ChemPartner) Plans to Raise Over RMB 930 Million in Private Placement

Fineline Cube Dec 16, 2024

Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149), is poised to raise...

Company Deals

AbbVie Acquires Roche’s Nimble Therapeutics to Boost Immunology Pipeline

Fineline Cube Dec 16, 2024

US pharmaceutical company AbbVie (NYSE: ABBV) has reached an agreement to acquire Swiss pharmaceutical giant...

Company Deals

iFlytek’s Xunfei Healthcare Passes HKEX Hearing for AI-Powered Medical IPO

Fineline Cube Dec 16, 2024

Xunfei Healthcare Technology Co., Ltd., a subsidiary of China’s leading information technology company iFlytek Co.,...

Company Deals

Innovent Biologics Partners with Eli Lilly for Distribution of Jaypirca in China

Fineline Cube Dec 16, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has entered into a significant distribution and promotion agreement...

Posts pagination

1 … 226 227 228 … 647

Recent updates

  • Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications
  • Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data
  • Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders
  • Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis
  • Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Others

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Company Drug

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.